Strides Shasun is currently trading at Rs. 418.50, up by 13.65 points or 3.37% from its previous closing of Rs. 404.85 on the BSE.
The scrip opened at Rs. 406.95 and has touched a high and low of Rs. 419.65 and Rs. 406.95 respectively. So far 213123 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1,128.09 on 24-Jul-2017 and a 52 week low of Rs. 334.10 on 08-Jun-2018.
Last one week high and low of the scrip stood at Rs. 419.70 and Rs. 352.50 respectively. The current market cap of the company is Rs. 3625.39 crore.
The promoters holding in the company stood at 31.36%, while Institutions and Non-Institutions held 51.32% and 17.32% respectively.
Strides Shasun’s wholly owned subsidiary -- Strides Pharma Global has received final approval for Ketoconazole Tablets USP, 200 mg from the United States Food & Drug Administration (US FDA). Ketoconazole Tablets is a generic version of Nizoral Tablets, 200 mg, of Janssen Pharmaceuticals.
Ketoconazole belongs to the class of drugs called azole antifungals. Ketoconazole is used to treat certain serious fungal infections in the body and it works by stopping the growth of the fungus.
As per IQVIA MAT April 2018 data, the US market for Ketoconazole Tablets was approximately $7 million. The product will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma in the US Market.
Strides Shasun is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The company has 74 cumulative ANDA filings with USFDA of which 47 ANDAs have been approved as of date and 27 are pending approval.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: